Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9
Open accessThe DOI matches its Crossref record; 68 of the 69 references it cites were found in a registry or an index.
Abstract
Variable regions 1 and 2 (V1/V2) of human immunodeficiency virus-1 (HIV-1) gp120 envelope glycoprotein are critical for viral evasion of antibody neutralization, and are themselves protected by extraordinary sequence diversity and N-linked glycosylation. Human antibodies such as PG9 nonetheless engage V1/V2 and neutralize 80% of HIV-1 isolates. Here we report the structure of V1/V2 in complex with PG9. V1/V2 forms a four-stranded β-sheet domain, in which sequence diversity and glycosylation are largely segregated to strand-connecting loops. PG9 recognition involves electrostatic, sequence-independent and glycan interactions: the latter account for over half the interactive surface but are of sufficiently weak affinity to avoid autoreactivity. The structures of V1/V2-directed antibodies CH04 and PGT145 indicate that they share a common mode of glycan penetration by extended anionic loops. In addition to structurally defining V1/V2, the results thus identify a paradigm of antibody recognition for highly glycosylated antigens, which-with PG9-involves a site of vulnerability comprising just two glycans and a strand.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Sometimes, such protective glycosylation can become so dense that it generates unique clustered epitopes recognized by speci fi c antibodies, such as that seen on the surface of the HIV virion (507 -509, 594).”
From Biological roles of glycans (2017) · cites this paper as [507]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coot : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571
Phaser crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612 · cited 1×
“and a molecular replacement solution for the 1FD6-ZM109 data set consisting of two unbound PG9 Fab molecules per asymmetric unit was obtained using PHASE”
The PyMOL Molecular Graphics System
DeLano, W. L. (2002) · Medical Entomology and Zoology · Cited by 18,147
Crystallography & NMR System: A New Software Suite for Macromolecular Structure Determination
Brünger, A. T., Adams, P. D., Clore, G. M., DeLano, W. L., Gros, P., Grosse-Kunstleve, R. W., Jiang, J. S., Kuszewski, J., Nilges, M., Pannu, N. S., et al. (1998) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444998003254 · Cited by 15,715
Overview of the CCP 4 suite and current developments
Winn, M. D., Ballard, C. C., Cowtan, K. D., Dodson, E. J., Emsley, P., Evans, P. R., Keegan, R. M., Krissinel, E. B., Leslie, A. G. W., McCoy, A., et al. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910045749 · Cited by 12,353
Inference of Macromolecular Assemblies from Crystalline State
Krissinel, E., & Henrick, K. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.05.022 · Cited by 9,984
Nicholls, A., Sharp, K. A., & Honig, B. (1991) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.340110407 · Cited by 5,240
PHENIX : building new software for automated crystallographic structure determination
Adams, P. D., Grosse-Kunstleve, R. W., Hung, L.-W., Ioerger, T. R., McCoy, A. J., Moriarty, N. W., Read, R. J., Sacchettini, J. C., Sauter, N. K., & Terwilliger, T. C. (2002) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444902016657 · Cited by 4,361
MolProbity: all-atom contacts and structure validation for proteins and nucleic acids
Davis, I. W., Leaver-Fay, A., Chen, V. B., Block, J. N., Kapral, G. J., Wang, X., Murray, L. W., Arendall, W. B., Snoeyink, J., Richardson, J. S., et al. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm216 · Cited by 3,896
The Anatomy and Taxonomy of Protein Structure
Richardson, J. S. (1981) · Advances in Protein Chemistry · doi:10.1016/s0065-3233(08)60520-3 · Cited by 3,375
Research works printed but not linked: 3
- Karasavvas, N. et al. The Thai Phase III clinical trial (RV144) induces the generation of antibodies that target a conserved region within the V2 loop of gp120. AIDS Res. Hum. Retroviruses 27, A-29 (2011) · DOI
- Zolla-Pazner, S. et al. V2-reactive antibodies in RV144 vaccinees’ plasma. AIDS Res. Hum. Retroviruses 27, A-21 (2011)
- Otwinowski, Z. & Minor, W. in Methods Enzymol. Vol. 276, 307–326 (Academic Press, 1997)
Cited by
Items 401–500 of 831
Antigenicity and Immunogenicity in HIV-1 Antibody-Based Vaccine Design
Kong, L., & Sattentau, Q. J. (2012) · Journal of AIDS & Clinical Research · doi:10.4172/2155-6113.s8-003 · Cited by 28
Banach, B. B., Pletnev, S. V., Olia, A. S., Xu, K. Y., Zhang, B., Rawi, R., Bylund, T., Doria‐Rose, N. A., Nguyen, T. D., Fahad, A. S., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42098-5 · Cited by 30
Self-citationHabib, A., Liang, Y., Xu, X., Zhu, N., & Xie, J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25042432 · Cited by 29
“Gp120 is extremely significant in the process of virus infection as it brings about the identification of specific receptors, including DC-SIGN, heparan-sulfate proteoglycans, and CD4 on the T cells of the host [7].”
BackgroundFlemming, J., Wiesen, L., & Herschhorn, A. (2018) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2018.0102 · Cited by 30
“63,75 The V1/V2 loop-directed bNAbs exhibit a long complementarity-determining region of the heavy chain (typically 26–30 amino acid long), 76 which penetrates the Env glycan shield around the V1/V2 epitope to bind conserved target sites, and they contain small– moderate number of somatic mutations.”
Moysi, E., Petrovas, C., & Koup, R. A. (2018) · Retrovirology · doi:10.1186/s12977-018-0437-y · Cited by 33
van Eeden, C., Wibmer, C. K., Scheepers, C., Richardson, S. I., Nonyane, M., Lambson, B. E., Mkhize, N. N., Balakrishnan, V., Sheng, Z., Stanfield-Oakley, S., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.11.058 · Cited by 27
“This differs from bNAbs, which only bind conformational epitopes that include region 167–181 as one of five b-strands forming part of a ‘‘Greek key motif’’ in prefusion Env trimers (Gorman et al., 2016; Julien et al., 2013;McLellan et al., 2011; Pancera et al., 2014).”
BackgroundSelf-citationeCD4-Ig Limits HIV-1 Escape More Effectively than CD4-Ig or a Broadly Neutralizing Antibody
Fellinger, C. H., Gardner, M. R., Weber, J. A., Alfant, B., Zhou, A. S., & Farzan, M. (2019) · Journal of Virology · doi:10.1128/jvi.00443-19 · Cited by 29
A naturally arising broad and potent CD4-binding site antibody with low somatic mutation
Barnes, C. O., Schoofs, T., Gnanapragasam, P. N. P., Golijanin, J., Huey‐Tubman, K. E., Gruell, H., Schommers, P., Suh-Toma, N., Lee, Y. E., Lorenzi, J. C. C., et al. (2022) · Science Advances · doi:10.1126/sciadv.abp8155 · Cited by 29
A New Approach to Produce HIV-1 Envelope Trimers
AlSalmi, W., Mahalingam, M., Ananthaswamy, N., Hamlin, C., Flores, D., Gao, G., & Rao, V. B. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.656611 · Cited by 27
“The contact regions include, primarily, the V1V2 loop glycans Asn-160 and Asn-156/173, and residue Lys-168 of one protomer and glycans Asn-160 and Asn-197 (V3 loop) of the adjacent protomer (29, 71, 72).”
BackgroundBenjelloun, F., Lawrence, P., Verrier, B., Genin, C., & Paul, S. (2012) · Journal of Virology · doi:10.1128/jvi.01110-12 · Cited by 29
“The top of the loop of CDRH3 of 4E10 forms a flat hydrophobic surface which suggests a possible interaction with the membrane of the virus.”
BackgroundInfluentialWillis, J. R., Finn, J. A., Briney, B. S., Sapparapu, G., Singh, V., King, H. A. D., LaBranche, C. C., Montefiori, D. C., Meiler, J., & Crowe, J. E. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1518405113 · Cited by 26
“PB, which were determined previously to bind PG9wt strongly (11).”
BackgroundMethodInfluentialLiang, Y., Guttman, M., Williams, J. A., Verkerke, H., Alvarado, D., Hu, S.-L., & Lee, K. K. (2016) · Journal of Virology · doi:10.1128/jvi.01116-16 · Cited by 31
Stéfic, K., Bouvin-Pley, M., Essat, A., Visdeloup, C., Moreau, A., Goujard, C., Chaix, M., Braibant, M., Meyer, L., & Barin, F. (2018) · Journal of Virology · doi:10.1128/jvi.01492-18 · Cited by 27
“interacting strand C for the V1V2 region (40, 41) and the PNGS N332 for the V3 region (42, 43).”
BackgroundSun, L., Paschall, A. V., Middleton, D. R., Ishihara, M., Ozdilek, A., Wantuch, P. L., Aceil, J., Duke, J. A., LaBranche, C. C., Tiemeyer, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16319-0 · Cited by 27
Perez, L. G., Chen, H., Liao, H., & Montefiori, D. C. (2014) · Journal of Virology · doi:10.1128/jvi.03296-13 · Cited by 35
“ing the HIV-1 V1V2 loop can block 4 7-gp120 binding (15).”
BackgroundO’Rourke, S. M., Schweighardt, B., Phung, P., Mesa, K. A., Vollrath, A. L., Tatsuno, G. P., To, B., Sinangil, F., Limoli, K. L., Wrin, T., et al. (2012) · Journal of Virology · doi:10.1128/jvi.01352-12 · Cited by 26
“The wtR clone was resistant to neutralization by the b12, PG16, and 4E10 MAbs but showed weak sensitivity to neutralization by the PG9 MAb.”
BackgroundInfluentialBioinformatic Analysis of HIV-1 Entry and Pathogenesis
Aiamkitsumrit, B., Dampier, W., Antell, G. C., Rivera, N., Martín‐García, J., Pirrone, V., Nonnemacher, M. R., & Wigdahl, B. L. (2014) · Current HIV Research · doi:10.2174/1570162x12666140526121746 · Cited by 32
“The first and second variable loops (V1 and V2) represent the largest part of gp120 and play an important role in envelope assembly and function, viral entry, antibodyinduced neutralization, CD4 binding, co-receptor usage, and viral spread [48-53].”
BackgroundM13 Virus Triboelectricity and Energy Harvesting
Kim, H., Lee, J., Lee, J. H., Lee, B. Y., Lee, B. D., Okada, K., Ji, S., Yoon, J., Lee, J. H., & Lee, S. (2021) · Nano Letters · doi:10.1021/acs.nanolett.1c01881 · Cited by 27
Lusvarghi, S., Lohith, K., Morin‐Leisk, J., Ghirlando, R., Hinshaw, J. E., & Bewley, C. A. (2016) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.6b00139 · Cited by 26
Self-citationExploiting glycan topography for computational design of Env glycoprotein antigenicity
Yu, W., Zhao, P., Draghi, M., Arevalo, C. P., Karsten, C. B., Suscovich, T. J., Gunn, B. M., Streeck, H., Brass, A. L., Tiemeyer, M., et al. (2018) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1006093 · Cited by 27
“However, while certain glycans may help shape individual epitopes [30, 31, 33, 34, 36, 51], glycans interact with one another, dynamically reshaping the exposed protein surface, coordinately influencing Ab binding access [37, 52–56].”
BackgroundSelf-citationRationally designed carbohydrate-occluded epitopes elicit HIV-1 Env-specific antibodies
Zhu, C., Dukhovlinova, E., Ping, L., Faison, E. M., Prabhu, S. S., Potter, E. L., Upton, S. L., Yin, G., Fay, J. M., Kincer, L. P., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-08876-w · Cited by 28
Conformational Flexibility in Respiratory Syncytial Virus G Neutralizing Epitopes
Fedechkin, S. O., George, N. L., Nuñez Castrejon, A. M., Dillen, J. R., Kauvar, L. M., & DuBois, R. M. (2020) · Journal of Virology · doi:10.1128/jvi.01879-19 · Cited by 26
Catching HIV ‘in the act’ with 3D electron microscopy
Earl, L. A., Lifson, J. D., & Subramaniam, S. (2013) · Trends in Microbiology · doi:10.1016/j.tim.2013.06.004 · Cited by 30
Evolution of B cell analysis and Env trimer redesign
Hedestam, G. B. K., Guenaga, J., Corcoran, M., & Wyatt, R. T. (2017) · Immunological Reviews · doi:10.1111/imr.12515 · Cited by 26
Self-citationBalasubramanian, P., Williams, C. A. U., Shapiro, M. B., Sinangil, F., Higgins, K. W., Nadas, A. J., Totrov, M. M., Kong, X., Fiore-Gartland, A. J., Haigwood, N. L., et al. (2018) · Scientific Reports · doi:10.1038/s41598-017-18863-0 · Cited by 26
Madan, B., Zhang, B., Xu, K. Y., Chao, C. W., O'Dell, S. J., Wolfe, J. R., Chuang, G., Fahad, A. S., Geng, H., Kong, R., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2011653118 · Cited by 30
“Several HIV-1 vulnerable epitopes have been described (5) including the following: the V1V2 apex (6, 7), the CD4-binding site (8–10), the membrane-proximal external region (11, 12), the glycan-V3 region (also known as N332 glycan supersite) (10, 13), the highly glycosylated region at the center of the silent face on t…”
BackgroundSelf-citationKreer, C., Lupo, C., Ercanoglu, M. S., Gieselmann, L., Spisak, N., Großbach, J., Schlotz, M., Schommers, P., Gruell, H., Dold, L., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42906-y · Cited by 22
Characterizing Carbohydrate–Protein Interactions by Nuclear Magnetic Resonance Spectroscopy
Bewley, C. A., & Shahzad‐ul‐Hussan, S. (2013) · Biopolymers · doi:10.1002/bip.22329 · Cited by 24
Self-citationKuwata, T., Takaki, K., Yoshimura, K., Enomoto, I., Wu, F., Ourmanov, I., Hirsch, V. M., Yokoyama, M., Sato, H., & Matsushita, S. (2013) · Journal of Virology · doi:10.1128/jvi.00201-13 · Cited by 25
Craig, R., Summa, C. M., Corti, M., & Pincus, S. H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046778 · Cited by 25
Gift, S. K., Leaman, D. P., Zhang, L., Kim, A. S., & Zwick, M. B. (2017) · Journal of Virology · doi:10.1128/jvi.01216-17 · Cited by 25
“V2 bnAbs typically have long tyrosine-sulfated CDR H3s that interact with positively charged lysine residues in the C strand, including K168, K169, and K171 (21, 25, 26), but glycans proximal to N160 can also influence binding and neutralization (27, 28).”
BackgroundWhat if protective immunity is antigen—driven and not due to so‐called “memory” B and T cells?
Zinkernagel, R. M. (2018) · Immunological Reviews · doi:10.1111/imr.12648 · Cited by 27
T follicular helper cells and HIV/SIV-specific antibody responses
Petrovas, C., & Koup, R. A. (2014) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000053 · Cited by 26
Wu, X., & Kong, X. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.05.013 · Cited by 24
“Crystal structures of PG9 and PG16 in complex with scaffolded V1V2 have shown that the epitopes of these two bnAbs (Figure 1) consist of Strand C and two glycans at N160 (HXB2 numbering) and N156 or N173 [38,39].”
Efficacy of broadly neutralizing monoclonal antibody PG16 in HIV-infected humanized mice
Stoddart, C. A., Galkina, S. A., Joshi, P., Kosikova, G., Long, B. R., Maidji, E., Moreno, M. E., Rivera, J. M., Sanford, U. R., Sloan, B. A., et al. (2014) · Virology · doi:10.1016/j.virol.2014.05.036 · Cited by 24
“PG16 targets the V1/V2 loop region at residues 160 and 162, corresponding to a potential N-linked glycosylation site that may form the PG16 epitope (McLellan et al., 2011; Pejchal et al., 2010; Walker et al., 2009).”
BackgroundDemirkhanyan, L. H., Marin, M., Lu, W., & Melikyan, G. B. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003431 · Cited by 24
Zhang, M.-Y., Yuan, T., Li, J., Borges, A. R., Watkins, J. D., Guenaga, J., Yang, Z., Wang, Y., Wilson, R., Li, Y., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044241 · Cited by 25
“PG9 binds to a site of vulnerability comprising of two conserved glycans and one of the four b-strands formed by the V1/V2 loops with the long protruding H3 loop penetrating the glycan shield [19].”
Self-citationSingle genome analysis reveals genetic characteristics of Neuroadaptation across HIV-1 envelope
Evering, T. H., Kamau, E. T., Bernard, L. S., Farmer, C. B., Kong, X., & Markowitz, M. H. (2014) · Retrovirology · doi:10.1186/s12977-014-0065-0 · Cited by 24
“The residues in the V2 tip cluster are located at the tip of the strands B and C of V1V2 [84] which is packed against the other 2 molecules in the trimer (trimer association), thus they will likely play a role in the trimer formation.”
BackgroundBroadly Neutralizing Antibodies against HIV-1 As a Novel Aspect of the Immune Response
Щербаков, Д. Н., Bakulina, A., Карпенко, Л. И., & Ilyichev, A. A. (2015) · Acta Naturae · doi:10.32607/20758251-2015-7-4-11-21 · Cited by 24
Chand, S., Messina, E., AlSalmi, W., Ananthaswamy, N., Gao, G., Uritskiy, G., Padilla-Sanchez, V., Mahalingam, M., Peachman, K. K., Robb, M. L., et al. (2017) · Virology · doi:10.1016/j.virol.2017.05.016 · Cited by 25
“Third, the quaternary broadly neutralizing antibody (BnAb) PG9, which recognizes the mannose glycans at positions N160 and N156 and the overall cationic nature of the C β-strand (McLellan et al., 2011) reacted with gp16-V1V2 Chand et al.”
BackgroundBharadwaj, P., Riekofski, C., Lin, S., Seaman, M. S., Garber, D. A., Montefiori, D. C., Sarzotti‐Kelsoe, M., Ackerman, M. E., & Weiner, J. A. (2020) · Journal of Immunological Methods · doi:10.1016/j.jim.2020.112764 · Cited by 22
Envelope Glycoprotein Trimers as HIV-1 Vaccine Immunogens
Sattentau, Q. J. (2013) · Vaccines · doi:10.3390/vaccines1040497 · Cited by 27
“However, recent crystallographic studies have revealed that glycans can also entirely comprise [33], or be a significant part [34–36], of neutralizing antibody epitopes, and so may in fact turn out to be part of the solution to the problem.”
BackgroundContrasting antibody responses to intrasubtype superinfection with CRF02_AG
Courtney, C. R., Mayr, L. M., Nanfack, A. J., Banin, A. N., Tuen, M., Pan, R., Jiang, X., Kong, X., Kirkpatrick, A. R., Bruno, D. P., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0173705 · Cited by 23
“…that react well with samples from CRF02_AG infected individuals (unpublished data Duerr lab) including: a scaffolded V1V2 protein (V1V2 ZM109-1FD6) [34], a cyclic V3 peptide (V3 ZM109) [35], gp120core JRFL [36], BG505 SOSIP [37] (S1 Meth-ods), and an MPER gp41 peptide (NIH AIDS Reagent Program,…”
A Structural Update of Neutralizing Epitopes on the HIV Envelope, a Moving Target
Miller, E. P., Finkelstein, M. T., Erdman, M. C., Seth, P. C., & Fera, D. (2021) · Viruses · doi:10.3390/v13091774 · Cited by 28
“They form beta strands, stabilized by interstrand disulfide bridges, at the cationic Env trimer apex [55,57,58].”
BackgroundFerguson, A. L., Falkowska, E., Walker, L. M., Seaman, M. S., Burton, D. R., & Chakraborty, A. K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080562 · Cited by 22
Self-citationStructure and Computation in Immunoreagent Design: From Diagnostics to Vaccines
Gourlay, L. J., Peri, C., Bolognesi, M., & Colombo, G. (2017) · Trends in biotechnology · doi:10.1016/j.tibtech.2017.06.018 · Cited by 23
A Highly Unusual V1 Region of Env in an Elite Controller of HIV Infection
Silver, Z. A., Dickinson, G. M., Seaman, M. S., & Desrosiers, R. C. (2019) · Journal of Virology · doi:10.1128/jvi.00094-19 · Cited by 23
“resistant to neutralization by all four tested V1/V2-glycan-dependent antibodies, this phenotype might be explained by the N160Y substitution in NL-VA40774 (30).”
BackgroundMethodRosengarten, J. F., Schatz, S., Wolf, T., Barbe, S., & Stitz, J. (2022) · Virology · doi:10.1016/j.virol.2022.01.008 · Cited by 24
Dimitrov, J. D., Planchais, C., Scheel, T., Ohayon, D., Mesnage, S., Berek, C., Kaveri, S. V., & Lacroix‐Desmazes, S. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.556266 · Cited by 24
“Each HIV-1-neutralizing antibody was injected for 5 min at the following concentrations: 5 nM (b12), 20 nM (VRC01), 100 nM (447-52D and 2G12), and 500 nM (PG9).”
BackgroundInfluentialJobe, O., Trinh, H. V., Kim, J., AlSalmi, W., Tovanabutra, S., Ehrenberg, P. K., Peachman, K. K., Gao, G., Thomas, R., Kim, J. H., et al. (2015) · Journal of Leukocyte Biology · doi:10.1189/jlb.2a0815-361r · Cited by 22
“Although there might be other regions of the envelope protein that could also bind to Siglec-1, the location of the V1V2 region exposed at the apex of the envelope trimer spike [51] is probably the most accessible for interaction with the Siglec-1 receptor [51, 53].”
BackgroundHumoral and Innate Antiviral Immunity as Tools to Clear Persistent HIV Infection
Ferrari, G., Pollara, J., Tomaras, G. D., & Haynes, B. F. (2016) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiw555 · Cited by 25
Self-citationGlycans in HIV-1 vaccine design – engaging the shield
Deimel, L. P., Xue, X., & Sattentau, Q. J. (2022) · Trends in Microbiology · doi:10.1016/j.tim.2022.02.004 · Cited by 23
Zhang, Y., Li, Q., Luo, L., Duan, C., Shen, J., & Wang, Z. (2023) · Biotechnology Advances · doi:10.1016/j.biotechadv.2023.108143 · Cited by 24
Waltari, E., Jia, M., Jiang, C. S., Lü, H., Huang, J., Fernández, C., Finzi, A., Kaufmann, D., Markowitz, M. H., Tsuji, M., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00628 · Cited by 25
“These results are concordant with the importance of long heavy chain CDR3 in some HIV-1 bnAbs, allowing for reaching to deep and partially obscured regions of the HIV-1 envelope trimer (61, 62).”
ResultBehrens, A., Kumar, A., Medina-Ramírez, M., Cupo, A., Marshall, K., Portillo, V. M. C., Harvey, D. J., Ozorowski, G., Zitzmann, N., Wilson, I. A., et al. (2018) · Journal of Proteome Research · doi:10.1021/acs.jproteome.7b00639 · Cited by 24
Self-citationStructural Features of Broadly Neutralizing Antibodies and Rational Design of Vaccine
Zhou, T., & Xu, K. Y. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-0484-2_4 · Cited by 24
Self-citationExploiting B Cell Receptor Analyses to Inform on HIV-1 Vaccination Strategies
Kreer, C., Gruell, H., Mora, T., Walczak, A. M., & Klein, F. (2020) · Vaccines · doi:10.3390/vaccines8010013 · Cited by 29
“For example, bNAbs binding to the V1/V2 apex region typically carry CDRH3s of extraordinary length that are required to penetrate the extensive Env glycan shield [129,130].”
BackgroundRavenscroft, N., Costantino, P., Talaga, P., Rodríguez–Jiménez, R., & Egan, W. (2014) · Springer eBooks · doi:10.1007/978-3-662-45024-6_8 · Cited by 27
Morales, J. F., Morin, T. J., Yu, B., Tatsuno, G. P., O’Rourke, S. M., Theolis, R., Mesa, K. A., & Berman, P. W. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.554089 · Cited by 21
Towards functional antibody-based vaccines to prevent pre-erythrocytic malaria infection
Sack, B. K., Kappe, S. H. I., & Sather, D. N. (2017) · Expert Review of Vaccines · doi:10.1080/14760584.2017.1295853 · Cited by 20
“between bNAbs and their target epitopes on the HIV-1 Envelope protein now have been extensively characterized at the atomic level(49-53).”
BackgroundFlow virometric sorting and analysis of HIV quasispecies from plasma
Musich, T., Jones, J. C., Keele, B. F., Jenkins, L. M. M., Demberg, T., Uldrick, T. S., Yarchoan, R., & Robert-Guroff, M. (2017) · JCI Insight · doi:10.1172/jci.insight.90626 · Cited by 21
“Two broadly neutralizing antibodies directed to different epitopes on gp120, PG9, which recognizes a glycopeptide epitope located in the V1–V2 region (14), and VRC01, which recognizes the CD4-binding site (15), were conjugated to fluorochromes and used to sort virus for further downstream analysis.”
Methodde Taeye, S. W., Go, E. P., Sliepen, K., de la Peña, A. T., Badal, K., Medina-Ramírez, M., Lee, W.-H., Desaire, H., Wilson, I. A., Moore, J. P., et al. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.005396 · Cited by 24
“The V1V2 domain folds into a four stranded antiparallel -sheet Greek key motif in which strands A and B are connected by the flexible V1 loop and strands C and D by the flexible V2 loop (8, 12, 13, 26, 43).”
BackgroundSelf-citationCryo-EM structures of prefusion SIV envelope trimer
Gorman, J., Wang, C., Mason, R. D., Nazzari, A. F., Welles, H. C., Zhou, T., Bess, J. W., Bylund, T., Lee, M., Tsybovsky, Y., et al. (2022) · Nature Structural & Molecular Biology · doi:10.1038/s41594-022-00852-1 · Cited by 22
Self-citationCharacterization and Carbohydrate Specificity of Pradimicin S
Shahzad‐ul‐Hussan, S., Ghirlando, R., Dogo‐Isonagie, C., Igarashi, Y., Balzarini, J. M., & Bewley, C. A. (2012) · Journal of the American Chemical Society · doi:10.1021/ja303860m · Cited by 21
Self-citationBoyapalle, S., Xu, W., Raulji, P., Mohapatra, S., & Mohapatra, S. S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0135288 · Cited by 21
Novel vaccines: Technology and development
Patil, S. U., & Shreffler, W. G. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.05.021 · Cited by 25
“This continual evolution of host antibodies and HIV proteins can lead to finely tuned bNAbs with long anionic CDR3 regions that target conserved regions under the mutable Env glycan shield.(62) Hence the unusual structural characteristics of bNAbs can contribute to their functional neutralization ability, given the he…”
BackgroundPotential targets for therapeutic intervention and structure based vaccine design against Zika virus
Qadir, A., Riaz, M. N., SAEED, M. K., & Shahzad‐ul‐Hussan, S. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.07.014 · Cited by 21
Self-citationAntibodies: Computer-Aided Prediction of Structure and Design of Function
Sevy, A. M., & Meiler, J. (2014) · Microbiology Spectrum · doi:10.1128/microbiolspec.aid-0024-2014 · Cited by 23
“McLellan et al. pursued a similar strategy to create a discontinuous epitope-presenting scaffold with a respiratory syncytial virus (RSV) epitope (68).”
BackgroundBehren, S., & Westerlind, U. (2019) · Molecules · doi:10.3390/molecules24061004 · Cited by 21
“Crystal structures of PG9 and PG16 in complex with gp120 V1V2 showed that the antibodies interact with high mannose glycans at N160 and N156 or N173, and an adjacent V1V2 domain consisting of four antiparallel β-strands [97,98].”
BackgroundMap of SARS-CoV-2 spike epitopes not shielded by glycansPreprint
Sikora, M., von Bülow, S., Blanc, F. E. C., Gecht, M., Covino, R., & Hummer, G. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.07.03.186825 · Cited by 21
Li, Y., Deng, L., Liang, J., Dong, G.-H., Xia, Y.-L., Fu, Y., & Liu, S.-Q. (2020) · Physical Chemistry Chemical Physics · doi:10.1039/c9cp06706j · Cited by 20
Vaccines based on structure-based design provide protection against infectious diseases
Thomas, S., & Luxon, B. A. (2013) · Expert Review of Vaccines · doi:10.1586/14760584.2013.840092 · Cited by 20
Mabuka, J. M., Goo, L., Omenda, M. M., Nduati, R. W., & Overbaugh, J. M. (2013) · AIDS · doi:10.1097/qad.0b013e32835faba5 · Cited by 20
Burton, S. L., Spicer, L. M., Charles, T. P., Gangadhara, S., Reddy, P. B. J., Styles, T. M., Velu, V., Kasturi, S. P., Legere, T. H., Hunter, E., et al. (2019) · Journal of Virology · doi:10.1128/jvi.01846-18 · Cited by 20
von Bredow, B., Andrabi, R., Grunst, M. W., Grandea, A. G., Le, K. M., Song, G., Berndsen, Z. T., Porter, K., Pallesen, J., Ward, A. B., et al. (2019) · mBio · doi:10.1128/mbio.01255-19 · Cited by 25
“distinguishes it from other V2 apex bNAbs (15, 16, 25).”
BackgroundSelf-citationGach, J. S., Quendler, H., Tong, T., Narayan, K. M., Du, S. X., Whalen, R. G., Binley, J. Μ., Forthal, D. N., Poignard, P., & Zwick, M. B. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072054 · Cited by 21
Brandenberg, O. F., Rusert, P., Magnus, C., Weber, J., Böni, J., Günthard, H. F., Regoes, R. R., & Trkola, A. (2014) · Retrovirology · doi:10.1186/preaccept-1148975491133162 · Cited by 20
Structural dynamics reveal isolate-specific differences at neutralization epitopes on HIV Env
Hodge, E. A., Naika, G. S., Kephart, S. M., Nguyen, A., Zhu, R., Benhaim, M. A., Guo, W., Moore, J. P., Hu, S., Sanders, R. W., et al. (2022) · iScience · doi:10.1016/j.isci.2022.104449 · Cited by 19
2G12-Expressing B Cell Lines May Aid in HIV Carbohydrate Vaccine Design Strategies
Doores, K. J., Huber, M., Le, K. M., Wang, S., Doyle-Cooper, C., Cooper, A. B., Pantophlet, R. A., Wong, C., Nemazee, D. A., & Burton, D. R. (2012) · Journal of Virology · doi:10.1128/jvi.02820-12 · Cited by 18
“(3, 4), 2G12 has been shown to bind glycans alone.”
BackgroundSelf-citationHamoudi, M., Simon‐Lorière, E., Gasser, R., & Negroni, M. (2013) · Retrovirology · doi:10.1186/1742-4690-10-114 · Cited by 21
“The vertical gray bars define the borders of the structural domains defined by McLellan and colleagues [31].”
InfluentialSaha, P., Bhattacharyya, S., Kesavardhana, S., Miranda, E. R., Ali, P. S. S., Sharma, D., & Varadarajan, R. (2012) · Biochemistry · doi:10.1021/bi300003v · Cited by 18
Tyrosine-sulfated V2 peptides inhibit HIV-1 infection via coreceptor mimicry
Cimbro, R., Peterson, F. C., Liu, Q., Guzzo, C., Zhang, P., Miao, H., Ryk, D. V., Ambroggio, X. I., Hurt, D. E., GIOIA, L. D., et al. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.06.037 · Cited by 19
van Diepen, M. T., Chapman, R. E., Moore, P. L., Margolin, E., Hermanus, T., Morris, L., Ximba, P., Rybicki, E. P., & Williamson, A. (2018) · PLoS ONE · doi:10.1371/journal.pone.0208310 · Cited by 22
Heredia, J. D., Park, J., Choi, H. S. J., Gill, K. S., & Procko, E. (2019) · Journal of Virology · doi:10.1128/jvi.00219-19 · Cited by 17
Immune Correlates of Disease Progression in Linked HIV-1 Infection
Tuen, M., Bimela, J. S., Banin, A. N., Ding, S., Harkins, G. W., Weiß, S., Itri, V., Durham, A. R., Porcella, S. F., Soni, S., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01062 · Cited by 20
“ELISA Plasma-purified IgG binding experiments were performed against a set of HIV-1 gp120 and gp41 antigens, including a scaffolded V1V2 protein (V1V2/ZM109-1FD6), (46, 78) a cyclic V3 peptide (V3/ZM109), (49, 80) gp120core JRFL, (50, 81) BG505 SOSIP, (51, 82) and an MPER gp41/con B peptide (NIH AIDS Reagent Program)…”
Chapman, R. E., van Diepen, M. T., Galant, S., Kruse, E., Margolin, E., Ximba, P., Hermanus, T., Moore, P. L., Douglass, N., Williamson, A., et al. (2020) · Vaccines · doi:10.3390/vaccines8010054 · Cited by 19
“Binding ELISAs to CAP256 SU V1V2 loop scaffolded protein [21] for week 0 and 2 weeks after the final MVA inoculation or protein boost were performed in a similar fashion, but plates were coated with 500ng / well of protein.”
MethodA Twin-Cysteine Motif in the V2 Region of gp120 Is Associated with SIV Envelope Trimer Stabilization
Bohl, C. R., Bowder, D., Thompson, J., Abrahamyan, L. G., González-Ramírez, S., Mao, Y., Sodroski, J., Wood, C. A., & Xiang, S.-H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069406 · Cited by 20
Carbonetti, S., Oliver, B. G. G., Glenn, J. A., Stamatatos, L., & Sather, D. N. (2014) · PLoS ONE · doi:10.1371/journal.pone.0086905 · Cited by 18
HIV-1 Envelope Glycosylation and the Signal Peptide
Lambert, G. S., & Upadhyay, C. (2021) · Vaccines · doi:10.3390/vaccines9020176 · Cited by 18
“Adapted from McLellan et al., 2011 [50].”
Genetic Signatures of HIV-1 Envelope-mediated Bystander Apoptosis
Joshi, A., Lee, R. T. C., Mohl, J. E., Sedano, M. J., Khong, W. X., Ng, O. T., Maurer‐Stroh, S., & Garg, H. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.514018 · Cited by 18
“Position, amino acid position based on HXB2 protein sequence starting from the first methionine residue of GP120; 3U2S, crystal structure of PG9 Fab in complex with the V1V2 region from HIV-1 strain ZM109 (52); 2QAD, structure of tyrosine-sulfated 412d antibody complexed with HIV-1 YU2 gp120 and CD4 (53); 2B4C, crysta…”
BackgroundMethodChaillon, A., Braibant, M., Hué, S., Bencharif, S., Enard, D., Moreau, A., Samri, A., Agut, H., & Barin, F. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044163 · Cited by 18
“Similarly, neither loss of potential N-glycosylation sites (PNGS) at positions 156, 160 and 173 nor single mutations previously shown to impact PG9 and PG16 sensitivity were observed among the 13 variants [57–59].”
BackgroundCai, H., Orwenyo, J., Guenaga, J., Giddens, J. P., Toonstra, C., Wyatt, R. T., & Wang, L. (2017) · Chemical Communications · doi:10.1039/c7cc02059g · Cited by 19
Self-citationEngineering broadly neutralizing antibodies for HIV prevention and therapy
Hua, C. K., & Ackerman, M. E. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.01.013 · Cited by 18
“Shared features of bNAbs isolated from HIV-1-infected individuals include high levels of somatic hypermutation [87–89], with 40–100 nucleotide mutations present in the heavy chain variable region (VH) alone [57, 58, 61, 72, 89–92], high levels of insertions/deletions [93], and long CDR-H3 regions which facilitate pene…”
BackgroundThe structure of a LAIR1-containing human antibody reveals a novel mechanism of antigen recognition
Hsieh, F.-L., & Higgins, M. K. (2017) · eLife · doi:10.7554/elife.27311 · Cited by 19
Robotic selection for the rapid development of stable CHO cell lines for HIV vaccine production
O’Rourke, S. M., Byrne, G., Tatsuno, G. P., Wright, M., Yu, B., Mesa, K. A., Doran, R. C., Alexander, D. L., & Berman, P. W. (2018) · PLoS ONE · doi:10.1371/journal.pone.0197656 · Cited by 18
HIV broadly neutralizing antibody precursors to the Apex epitope induced in nonhuman primates
Krystal, M., Sutton, H. J., Pratap, P. P., Steichen, J. M., Carnathan, D. G., Quinn, J., Kalyuzhniy, O., Liguori, A., Agrawal, S., Baboo, S., et al. (2025) · Science Immunology · doi:10.1126/sciimmunol.adt6660 · Cited by 23
Self-citationCatch Me If You Can--The Race Between HIV and Neutralizing Antibodies.
Geiß, Y., & Dietrich, U. (2015) · PubMed · Cited by 24
Jianhui, T., López, C. A., Derdeyn, C. A., Jones, M. S., Pinter, A., Korber, B., & Gnanakaran, S. (2016) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1005094 · Cited by 18
“In the native trimer form of HIV-1, this region of V1V2 adopts a beta-strand conformation, which persists when it is bound to broadly neutralizing antibodies PG9 and PG16 [30, 44–46].”
BackgroundMethodInfluentialCrooks, E. T., Almanza, F., D’Addabbo, A., Duggan, E., Zhang, J., Wagh, K., Mou, H., Allen, J. D., Thomas, A., Osawa, K., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009807 · Cited by 18
How to drug a cloud? Targeting intrinsically disordered proteins
Uversky, V. N. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.124.001113 · Cited by 23
Metadata
- Authors
- McLellan, J. S., Pancera, M., Carrico, C., Gorman, J., Julien, J.-P., Khayat, R., Louder, R., Pejchal, R., Sastry, M., Dai, K., O’Dell, S., Patel, N., Shahzad-ul-Hussan, S., Yang, Y., Zhang, B., Zhou, T., Zhu, J., Boyington, J. C., Chuang, G.-Y., Diwanji, D., Georgiev, I., Do Kwon, Y., Lee, D., Louder, M. K., Moquin, S., Schmidt, S. D., Yang, Z.-Y., Bonsignori, M., Crump, J. A., Kapiga, S. H., Sam, N. E., Haynes, B. F., Burton, D. R., Koff, W. C., Walker, L. M., Phogat, S., Wyatt, R., Orwenyo, J., Wang, L.-X., Arthos, J., Bewley, C. A., Mascola, J. R., Nabel, G. J., Schief, W. R., Ward, A. B., Wilson, I. A., & Kwong, P. D.
- Affiliations
- National Institutes of Health (US)
- University of Washington (US)
- Scripps Research Institute (US)
- Duke University (US)
- Tumaini University (TZ)
- International AIDS Vaccine Initiative (US)
- University of Maryland, Baltimore (US)
- Corresponding author
- Kwong, Peter D.
- ORCID
- McLellan, Jason S.
- Pancera, Marie
- Carrico, Chris
- Gorman, Jason
- Julien, Jean-Philippe
- Khayat, Reza
- Louder, Robert
- Patel, Nikita
- Yang, Yongping
- Zhang, Baoshan
- Zhou, Tongqing
- Zhu, Jiang
- Boyington, Jeffrey C.
- Chuang, Gwo-Yu
- Diwanji, Devan
- Georgiev, Ivelin
- Louder, Mark K.
- Moquin, Stephanie
- Schmidt, Stephen D.
- Bonsignori, Mattia
- Crump, John A.
- Kapiga, Saidi H.
- Haynes, Barton F.
- Burton, Dennis R.
- Koff, Wayne C.
- Walker, Laura M.
- Wyatt, Richard
- Wang, Lai-Xi
- Arthos, James
- Bewley, Carole A.
- Mascola, John R.
- Nabel, Gary J.
- Schief, William R.
- Ward, Andrew B.
- Wilson, Ian A.
- Kwong, Peter D.
- Venue
- Nature
- Published
- 2011-11-23
- Volume
- 480
- Issue
- 7377
- Pages
- 336-343
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3406929
- OpenAlex
- W2122617162
- Cited by
- 830
- References
- 69
- Citations by year
- 2026: 22 · 2025: 21 · 2024: 23 · 2023: 25 · 2022: 36 · 2021: 38 · 2020: 39 · 2019: 52 · 2018: 63 · 2017: 70 · 2016: 64 · 2015: 84 · 2014: 92 · 2013: 120 · 2012: 78
- FWCI
- 36.97
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DukeSpace (Duke University) (submittedVersion, cc-by-nc-nd)
- Funders
- U.S. Department of Energy (W - 31 - 109 - Eng - 38)
- International AIDS Vaccine Initiative
- Ragon Institute of MGH, MIT and Harvard
- National Institutes of Health
- Office of Science (W-31-109-ENG-38)
- Canadian Institutes of Health Research
- National Institute of Allergy and Infectious Diseases (R01AI033292, R01AI084817)
- National Center for Research Resources (RR017573, P41RR017573)
- Basic Energy Sciences (W-31-109-Eng38)
- Topics
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Physical Sciences › Chemistry › Organic Chemistry › Carbohydrate Chemistry and Synthesis
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Keywords
- HIV-1 gp120, antibody-antigen complex structure, N-glycosylation, carbohydrate recognition, HIV vaccine development, envelope glycoprotein
- MeSH terms
- Amino Acid Sequence, Antibody Affinity, Antibody Specificity, Antigen-Antibody Complex, Epitopes, Binding Sites, Antibody, Glycopeptides, Glycosylation, Hydrogen Bonding, Models, Molecular, Molecular Sequence Data, Polysaccharides, HIV Antibodies, HIV-1, HIV Envelope Protein gp120, AIDS Vaccines, Conserved Sequence, Protein Structure, Tertiary, Crystallography, X-Ray, Amino Acid Motifs, Protein Structure, Quaternary, Immune Evasion, Antibodies, Neutralizing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.